Ponesimod S1P1 Modulation Reduces Corticosteroid Use in MS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple sclerosis, particularly in the degenerative phase, are less effective and often require high doses of corticosteroids, which can lead to adverse events and steroid resistance, necessitating a need for alternative therapies that reduce corticosteroid use.
Innovation Solution
Administering ponesimod, a selective S1P1 receptor modulator, in a regimen that effectively reduces the need for corticosteroids in managing multiple sclerosis, particularly in patients with relapsing forms of the disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of corticosteroids are used to treat multiple sclerosis relapses, then the immediate anti-inflammatory effect is improved, but adverse events and steroid resistance increase
Solution Approach 1:
Ponesimod acts as an intermediary agent that modulates the immune response by selectively targeting S1P1 receptors on lymphocytes. This mediator blocks lymphocyte egress from lymphoid organs, preventing their recruitment to sites of inflammation in the central nervous system, thereby providing anti-inflammatory effects without using high-dose corticosteroids and their associated harmful side effects
Solution Approach 2:
The invention changes the therapeutic parameter from corticosteroid dosage to S1P1 receptor modulation. By administering ponesimod at controlled doses (10-25 mg daily), the treatment achieves effective immune modulation while avoiding the dose-dependent adverse effects of high-dose corticosteroids, including steroid resistance, metabolic disturbances, and immunosuppression
2Productivity
If frequent corticosteroid treatments are administered to manage relapses, then the frequency of relapse management is improved, but cumulative adverse effects and steroid resistance worsen
Solution Approach 1:
Ponesimod is administered continuously at a low dose (10-25 mg daily) as a preliminary and sustained intervention that prevents lymphocyte recruitment to sites of inflammation before relapses occur. This continuous low-dose prevention strategy reduces the need for frequent high-dose corticosteroid treatments, thereby avoiding cumulative adverse effects while maintaining effective relapse management
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Ponesimod treatment significantly lowers the frequency and dose of corticosteroid use, improving patient outcomes and reducing adverse effects associated with high-dose corticosteroid therapy.
Implementation Method 1
S1P1 receptor modulators block lymphocyte migration out of lymphoid tissue into the lymphatic and vascular circulation, thereby reducing peripheral lymphocyte counts and preventing lymphocyte recruitment to sites of inflammation
Data Source
AI summary
The disclosure relates to methods of treating multiple sclerosis. In certain aspects, methods of reducing corticosteroid use in a patient with multiple sclerosis are disclosed.